1. Introduction
===============

Reemergence of severe acute respiratory syndrome (SARS) is a distinct possibility. Currently neither antiviral therapy nor vaccine is available. Viral replicase and protease are preferred targets for the screening and design of antiviral compounds and have been successfully targeted in several viral diseases. The SARS-associated coronavirus (SARS-CoV) main proteinase (Mpro or 3CL pro) plays a key role in proteolytic processing of the replicase polyproteins 1a and 1ab, which makes it an attractive target for developing drugs against this new disease. Recent report indicated that the proteinase inhibitor kaletra, a mixture of protease inhibitors----lopinavir and ritonavir, approved for treating HIV in 2000, shows signs of effectiveness against the SARS virus.[@BIB1] In particular, researchers in Taiwan discovered that two existing medicines, which have significant effect in inhibiting the replication of SARS-CoV (<http://www.etaiwannews.com/Taiwan/2003/10/31/1067562739.htm>). One is an anti-parasite drug niclosamide, and another is anti-psychotic drug promazine. The purpose of this study is to analyze whether the SARS-CoV main proteinase could be the target of these existing drugs. We performed in silico binding studies of the drugs using the recently identified crystal structure of Mpro,[@BIB2], [@BIB3] to provide information for anti-SARS inhibitor design.

2. Materials and methods
========================

The atomic coordinates of SARS-CoV main proteinase were downloaded from Protein Data Bank (PDB ID 1Q2W). Another crystal structure of SARS-CoV main proteinase is also available (PDB ID 1UJ1), the superposition of 1Q2W A chain and 1UJ1 A chain is shown in [Figure 1](#FIG1){ref-type="fig"} , they overlap very well (rmsd = 0.64), here we chose 1Q2W as docking studies, which was released early. The overall structure of a monomer of SARS-CoV main proteinase is composed of three domains: domain I (residues 1--101), domain II (residues 102--200) and III (residues 201--303), represented by green, pink and white trace in [Figure 1](#FIG1){ref-type="fig"}. The cleft between domains I and II is its substrate-binding site.Figure 1Superposition of two crystal structures from SARS-CoV main proteinase: 1Q2W A chain and 1UJ1 A chain. Domain I (residues 1--101, green trace), domain II (residues 102--200, pink trace) and III (residues 201--303, white trace).

Except four drugs (lopinavir, ritonavir, niclosamide and promazine), we also conducted the docking studies of two other molecules, PNU and UC2, for their molecular formulas are close to those of niclosamide and promazine, respectively ([Fig. 2](#FIG2){ref-type="fig"} ), and they both are the inhibitors of HIV-1 reverse transcriptase.[@BIB4], [@BIB5] The program Hex was employed to conduct the docking of the ligands to the SARS-CoV main proteinase, its basic approach to the docking problem is to model each molecule using 3D parametric functions, which encode both surface shape, electrostatic charge and potential distributions. The surface shape representation uses a novel 3D surface skin model of protein topology, and a novel soft molecular mechanics energy minimization procedure is used to refine the candidate docking solutions. Unlike conventional 3D fast Fourier transform (FFT) docking approaches, Hex uses spherical polar Fourier correlations to accelerate the docking between 10 and 100 times faster than FFT docking algorithm.[@BIB6] Here we used the following parameter set: correlation type = shape + three probes, post-processing = MM minimization, steric scan = 20 (maximum), final search = 32 (maximum), the others are default set. The structural comparison was performed by LGA.[@BIB7] The visualization of 3D structure was generated by PROTEINEXPLORER (<http://www.proteinexplorer.org>).Figure 2Chemical structures of drugs and inhibitors mentioned in this study: (a) lopinavir (C~37~H~48~N~4~O~5~), (b) ritonavir (C~37~H~48~N~6~O~5~S~2~), (c) niclosamide (C~13~H~8~Cl~2~N~2~O~4~), (d) promazine (C~17~H~20~N~2~S), (e) PNU (C~13~H~11~ClN~4~OS), (f) UC2 (C~17~H~19~ClN~2~O~2~S).

3. Results and discussion
=========================

[Figure 3](#FIG3){ref-type="fig"} displays the overall structures of docking for four drugs (lopinavir, ritonavir, niclosamide and promazine) and two inhibitors (PNU and UC2) to SARS-CoV main proteinase. The binding pockets of these compounds in SARS-CoV main protease are shown in [Table 1](#TBL1){ref-type="table"} , which is defined by those residues that have at least one heavy atom (other than hydrogen) with a distance less than 5 Å from a heavy atom of inhibitors, as described by Chou et al.[@BIB8] The results show that the binding pockets of six compounds can be divided into three classes: (1) residues 40--86 and 181--192 for four drugs/inhibitors (lopinavir, niclosamide, promazine and PNU); (2) residues 41--51 and 164--194 for UC2 inhibitor; (3) residues 19--57 and 117--193 for drug ritonavir. All these pockets locate in domain I (residues 8--101), domain II (residues 102--184) and a long loop region (residues 185--200) connecting domains I and II in SARS-CoV main proteinase. Thus, the four drugs and two inhibitors studied here can basically bind to the active site of SARS-CoV main proteinase, a cleft between domains I and II.Figure 3The binding pockets (pink ball-stick) of SARS-associated coronavirus main proteinase (white cartoon) with drugs and inhibitors (yellow spacefill): Anti-HIV drugs lopinavir (a) and ritonavir (b), anti-parasite drug niclosamide (c), anti-psychotic drug promazine (d), HIV inhibitors PNU (e) and UC2 (f).Table 1Binding pockets for SARS-CoV main proteinase with different drugsLopinavirRitonavirNiclosamidePromazinePNUUC2ARG 40GLN 19SER 123ARG 40ARG 40ARG 40HIS 41CYS 44VAL 20PHE 140MET 49ILE 43HIS 41MET 49MET 49THR 21LEU 141LEU 50CYS 44ILE 43LEU 50LEU 50CYS 22ASN 142ASN 51MET 49CYS 44ASN 51ASN 51GLY 23GLY 143PRO 52LEU 50MET 49HIS 164PRO 52THR 24SER 144ASN 53ASN 51LEU 50MET 165ASN 53THR 25CYS 145TYR 54PRO 52ASN 51GLU 166TYR 54THR 26GLY 146GLU 55ASN 53PRO 52LEU 167GLU 55LEU 27SER 147ASP 56TYR 54ASN 53PRO 168ASP 56ASN 28HIS 163LEU 57GLU 55TYR 54THR 169LEU 57PRO 39HIS 164MET 82ASP 56GLU 55GLY 170MET 82ARG 40MET 165VAL 186LEU 57ASP 56VAL 171ASN 84HIS 41GLU 166ASP 187LEU 58LEU 57HIS 172CYS 85VAL 42LEU 167ARG 188MET 82LEU 58ALA 173PHE 181ILE 43PRO 168GLN 189ASN 84MET 82PHE 181PHE 185CYS 44VAL 171THR 190CYS 85GLN 83PRO 184VAL 186MET 49HIS 172VAL 186ASN 84PHE 185ASP 187LEU 50ALA 173ASP 187CYS 85VAL 186ARG 188ASN 51GLY 174ARG 188LEU 86ASP 187GLN 189PRO 52PHE 181GLN 189VAL 186ARG 188THR 190ASN 53PHE 185THR 190ASP 187GLN 189ALA 191TYR 54VAL 186ARG 188THR 190GLN 192LEU 57ASP 187GLN 189ALA 191CYS 117ARG 188THR 190GLN 192TYR 118GLN 189ALA 193ASN 119THR 190ALA 194GLY 120ALA 191SER 121GLN 192ALA 193

To estimate the binding affinities of each compound, the inhibitory constant (*K* ~i~, mole) was calculated from the equation:ΔG=−RTlnKiwhere Δ*G* is the free energy of binding (kJ/mol) (here refers to the final docked energy), *R* is the gas constant 8.31 J/K/mol and *T* is the absolute temperature (at 300 K), as did in Jenwitheesuk and Samudrala.[@BIB9] The results indicate that the inhibitory constants of six compounds are: 8.7 × 10^−20^ (lopinavir), 5.6 × 10^−25^ (ritonavir), 4.2 × 10^−22^ (niclosamide), 6.2 × 10^−21^ (promazine), 3.5 × 10^−23^ (PNU), 2.1 × 10^−19^ (UC2). It is noted that these values are too low, for example, the inhibitory constant of lopinavir was determined as ∼10^−7^ by Jenwitheesuk and Samudrala.[@BIB10] The reason for this difference is that the docked energy value from Hex program is a pseudo-energy, which is designed to give reasonably consistent units with conventional energy calculations, not based on experimentally derived parameters, and as a theoretical reference value only when performing the docking algorithm. Thus we do not expect these values are the genuine representations of inhibitory constants and we use them primarily for qualitative comparison among the drugs/inhibitors studied here. Because the lower the *K* ~i~ is, the greater the binding affinity is, hence HIV drug ritonavir is the compound that bind to the substrate binding site of SARS-CoV proteinase with the highest binding affinity, followed by HIV inhibitor PNU and anti-parasite drug niclosamide, and UC2 is the compound with the lowest binding affinity. Moreover, the inhibitory constants of ritonavir, PNU, niclosamide, promazine and UC2 are about 10^−5^, 10^−3^, 10^−2^, 10^−1^ and 10-fold inhibitory constant of lopinavir, respectively, if we assume that a value of 10^−7^  mol for lopinavir\'s inhibitory constant is correct, the inhibitory constants of ritonavir, PNU, niclosamide, promazine and UC2 could be estimated as 10^−12^, 10^−10^, 10^−9^, 10^−8^ and 10^−6^  mol, respectively.

The close views of the interactions between SARS-CoV main proteinase and these drugs/inhibitors are exhibited in [Figure 4](#FIG4){ref-type="fig"} . The results show that half of lopinavir is left outside the catalytic site ([Fig. 4a](#FIG4){ref-type="fig"}), for ritonavir, the thiazole group (P1) and a benzene group (P2) are inserted into S1 and S2 specificity pockets, respectively, while another benzene side chain (P3) might be too long to fit the substrate binding pocket perfectly ([Fig. 4b](#FIG4){ref-type="fig"}), there is similar situation in the inhibitor AG7088,[@BIB11] which has been experimentally shown to not bind with high affinity to the SARS-CoV proteinase (<http://www.nature.com/nsu/030512/030512-11.html>). Thus the efficacy of lopinavir/ritonavir could be poor. Indeed, consistent with our predictions, experimental observation data indicated that both lopinavir and ritonavir individually have only a weak in vitro activity against SARS-CoV. However, the addition of lopinavir/ritonavir to ribavirin and corticosteroid treatment regimens appears to reduce incubation and mortality rates, especially when administered early.[@BIB12] Similarly, the half of niclosamide or promazine is left outside the active site ([Fig. 4c and d](#FIG4){ref-type="fig"}), obviously the propane side chain in promazine is too long. For PNU inhibitor, seems it can basically fit into the active cleft, except the dihydrofuran side chain is a little bit long ([Fig. 4e](#FIG4){ref-type="fig"}). Finally, the inhibitor UC2 binds to a position that is slightly away from the active centre ([Fig. 4f](#FIG4){ref-type="fig"}), its neopentane or methylfuran side chain is a little long and makes it unable to insert into the active pocket properly. Indeed UC2 is the compound with lowest binding affinity as mentioned above. Taken together, our study illustrates that existing drugs/inhibitors may be used as starting points for the discovery of rationally designed anti-SARS proteinase drugs.Figure 4A close view of the interactions between SARS-associated coronavirus main proteinase (white cartoon) with drugs and inhibitors (yellow ball-stick): (a) lopinavir, (b) ritonavir, (c) niclosamide, (d) promazine, (e) PNU and (f) UC2.
